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ABSTRACT 
Background and Objectives 
The advent of Highly Active Antiretroviral Therapy (HAART) has resulted in a 
significant reduction in HIV/AIDS related morbidity and mortality in sub-Saharan 
Africa. However, toxicities due to HAART continue to pose challenges to the success 
of different regimens. Severe hepatotoxicity is one of the significant adverse events 
occurring in patients on HAART. Information on the incidence and risk factors for 
severe hepatotoxicity in cohorts from resource poor settings is limited. It is against 
this background that we undertook the study to determine the incidence and explore 
factors associated with severe hepatotoxicity following HAART initiation in a South 
African cohort. 
 
Materials and Methods 
Secondary data analysis of a prospective cohort 9764 HIV-infected adult patients 
initiated on HAART at the Themba Lethu clinic antiretroviral rollout facility in 
Johannesburg, South Africa between 1st April 2004 and 30th June 2009 was 
conducted. Severe hepatotoxicity cases were identified within the first 12 months of 
initiating HAART as grade 3 or 4 elevation in baseline ALT levels. The incidence rate 
of severe hepatotoxicity was calculated and potential socio-demographic and clinical 
predictors were explored using Cox proportional hazard regression modelling. 
 
Results 
At baseline, 91.8% of patients were commenced on an efavirenz-based regimen 
while only 8.2% were on a nevirapine-based regimen. The median CD4 count at 
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initiation of HAART for this cohort was 80 cells/ mm3, a figure lower than the 
Department of Health (DoH) CD4 cut off for initiating HAART of 200 cells/ mm3. 
The overall incidence rate of severe hepatotoxicity was 10.7 (95% CI: 8.7 – 13.1) 
cases per 1000 p-yrs of follow-up. The period with the highest risk of severe 
hepatotoxicity was within 2 months of initiating HAART. Incidence of severe 
hepatotoxicity was 21.1(95% CI: 12.7 – 34.9) cases per 1000 p-yrs among patients 
on a nevirapine-based regimen and 9.7 (95% CI: 7.8 – 12.1) cases per 1000 p-yrs in 
those on an efavirenz-based one.  
The hazard for severe hepatotoxicity within the first year of initiating HAART was 
2.17 times higher in individuals on a nevirapine-based regimen compared to those 
on an efavirenz-based regimen after adjusting for baseline ALT, baseline CD4, age 
and gender (HR = 2.17; 95%CI = 1.18 – 3.97; p = 0.013). Though imprecise, the 
estimate for baseline ALT category suggested an increased risk for severe 
hepatotoxicity in individuals with a baseline ALT more than 40 I.U/L compared to 
those with a baseline ALT of less than 40 I.U/L (HR = 1.63; 95%CI = 1.00 – 2.67; p = 
0.050). 
 
Conclusion 
The results of the study suggest that severe hepatotoxicity following initiation of 
HAART in this cohort is low compared to other previously studied cohorts. The high 
incidence rate of severe hepatotoxicity in the first two months of initiating HAART 
necessitates the need for more frequent and careful monitoring of ALT levels early 
during therapy. Patients on a nevirapine-based regimen have a higher risk of 
developing severe hepatotoxicity when compared to their counterparts on an 
efavirenz-based regimen, a result consistent with findings from previous studies.      
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CHAPTER ONE 
 
INTRODUCTION 
Introduction: The significance of Highly Active Antiretroviral Therapy (HAART) 
programs in Sub-Saharan Africa, a region severely affected by HIV/AIDS, is 
discussed in this chapter. Hepatotoxicity in patients on HAART is reviewed. A 
discussion on published literature of factors associated with hepatotoxicity in patients 
on HAART is outlined. The chapter ends with the study’s aims and objectives 
outlined in the report.  
 
Background 
The introduction of highly active antiretroviral therapy (HAART) has improved 
survival and life expectancy in HIV-infected patients [1-5]. . However, this success 
has also resulted in the emergence of adverse events, some of which might interrupt 
antiretroviral therapy intake or adherence. Anaemia, skin rash, fat re-distribution 
syndrome, peripheral neuropathy and hepatotoxicity are among the most common 
adverse events following initiation of antiretroviral therapy by HIV-infected patients 
[3, 6-7].  
 
 Hepatotoxicity is one of the common adverse events in patients on antiretroviral 
therapy. It can result in interruption of therapy, clinical hepatitis and even death [8].  
All antiretroviral classes are associated with hepatotoxicity, though this is more 
commonly seen with the Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
[8-9]. The South African Department of Health (DoH) estimates that hepatotoxicity 
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occurs in 8-18% of patients on antiretroviral drugs and in some cases the event may 
even be fatal [10]. It is for this reason that the liver function of patients initiated on 
antiretroviral therapy is assessed by checking levels of liver enzymes regularly. 
 
While several retrospective and prospective clinic-based cohort studies in resource-
rich settings have examined associations between specific antiretroviral regimens, 
socio-demographic and clinical factors and the development of hepatotoxicity in 
patients initiated on antiretroviral therapy [3, 8, 11-18], the incidence and risk factors 
of antiretroviral-associated hepatotoxicity in resource poor settings has been 
described in a limited number of studies [19-22].   
 
Problem Statement 
The rapid scale up of HAART programmes in sub-Saharan Africa, a region at the 
epicentre of the HIV/AIDS epidemic, suggests that the incidence of antiretroviral 
associated hepatotoxicity may also rise. The serious complications of developing 
hepatotoxicity (clinical hepatitis or death) make the public health impact of 
hepatotoxicity of particular concern in our setting. While broad patterns of 
hepatotoxicity have emerged [13, 23], differing duration of clinical monitoring and 
lack of standardised definitions of hepatotoxicity in previous studies makes 
comparisons across studies difficult. 
 
Justification for study 
 Aside from the association with high morbidity and mortality, hepatotoxicity may also 
lead to interruption of and poor adherence to antiretroviral treatment [3]. It is 
therefore important to understand and explore possible factors associated with 
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hepatotoxicity in patients initiated on antiretroviral therapy. This information will 
assist policy makers to modify current guidelines to reduce the number of patients 
developing hepatotoxicity following initiation of antiretroviral therapy. Previous work 
in this field has largely been carried out in resource-rich settings where patient 
characteristics and antiretroviral regimens are different from resource-limited settings 
and hence their findings might not be applicable to this setting.  
 
Literature Review 
Scale of the HIV epidemic  
 The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimated that 1.9 
million people in Sub-Saharan Africa became newly infected with HIV in 2008 
bringing the total number of people living with HIV in this region to 22.4 million [5] . 
Treatment scale-up programmes in Sub-Saharan Africa have significantly reduced 
HIV-related mortality and orphan-hood [5]. In Botswana, where antiretroviral therapy 
coverage exceeds 80%, there has been a more than 50% decline of the annual 
number of AIDS-related deaths between 2003 and 2007, and a 40% decline in 
children newly orphaned by AIDS [24]. However, HAART use has also been 
associated with a number of adverse events, which include anaemia, skin rashes, 
peripheral neuropathy, fat re-distribution syndrome and hepatotoxicity [3, 6-8]. 
Severe hepatotoxicity is one of the frequently described life threatening adverse 
events encountered by patients on HAART [8]. This has necessitated the need for 
close patient monitoring during treatment.  
    
           Definitions of hepatotoxicity 
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According to the AIDS Clinical Trials Group (ACTG), liver enzyme elevations are 
categorised into four grades according to severity. The grades are based on 
elevation of Alanine aminotransferase (ALT) from the upper limit of normal (ULN): 
grade 0, <1.25 x ULN; grade 1, 1.25-2.5 x ULN; grade 2, 2.6-5 x ULN; grade 3, 5.1-
10 x ULN; and grade 4, > 10 x ULN [25]. Several different definitions of 
hepatotoxicity have been adopted across studies to date. Some studies have used 
grade 3 and 4 elevation of liver enzymes to define hepatotoxicity [8, 12-13, 15, 17, 
22, 26-27], whereas others have considered grade 1 elevation in liver enzymes [20, 
28] or grade 2 elevation in liver enzymes [29] to be evidence of hepatotoxicity.  
For the purposes of this study, severe hepatotoxicity is defined as ACTG grade 3 or 
4 elevation in ALT blood levels.        
           
         Incidence of severe hepatotoxicity 
There is limited information on the incidence of severe hepatotoxicity in a general 
HAART roll-out clinic in South Africa. An incidence rate of 77 cases per 1000 person-
years (p-yrs) of follow-up time has been reported in a study conducted on a South 
African cohort. However, the study was conducted in a mining environment where 
the participants were mainly male and a high proportion of individuals were on anti-
tuberculous drugs at the time of initiating HAART [26]. 
 An Italian study reported an incidence rate of severe hepatotoxicity of 177.1 per 
1000 p-yrs of follow-up time [30]. This study was done on a cohort that has different 
first-line HAART regimens from ours. 52% of the clients in this cohort were on a 
protease inhibitor and 48% were on an NNRTI-based regimen. All the participants in 
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this study were also co-infected with Hepatitis C virus (HCV) which is rare in sub-
Saharan Africa [31]. It is therefore difficult to extrapolate these results to our setting. 
 
  Risk factors for development of hepatotoxicity 
 Hepatotoxicity is a well described component of adverse events seen in patients on 
antiretroviral therapy and is seen with almost all classes of antiretroviral drugs [11-
13]. However, a number of studies have shown higher frequencies of hepatotoxicity 
in patients on nevirapine-based regimens (4-18%) compared to those on efavirenz-
based regimens (1-8%) [8, 14-15, 28]. 
 
HIV and hepatitis B virus (HBV) co-infection is more common in some parts of sub-
Saharan Africa than it is in resource-rich countries [20, 32]. Co-infection with HBV 
has been identified as an independent risk factor for severe hepatotoxicity in patients 
on antiretroviral therapy in South African cohorts [26, 33]. Similar results have also 
been noted in resource rich settings in Europe and China where patients co-infected 
with HBV are more likely to develop severe hepatotoxicity while on HAART 
compared to patients who are not [12-13, 28].  
Although HCV infection is not common in our setting [31], available evidence has 
consistently demonstrated that co-infection with HCV significantly increases the risk 
of HAART associated hepatotoxicity [34-35]. Several mechanisms may account for 
hepatotoxicity among patients with HIV/HCV co-infection. Firstly, HCV infection leads 
to significant underlying liver damage in an individual thereby increasing the 
susceptibility to potential hepatotoxic HAART drugs. Furthermore, HCV/HIV co-
infection has been demonstrated to result in accumulation of functional HIV-specific 
T-cells in the liver thereby resulting in accelerated progression of liver disease [36]. 
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Conflicting evidence exists as to whether a high CD4 count is a risk factor for 
hepatotoxicity in patients on a nevirapine-based HAART regimen. Female patients 
with CD4 counts greater than 250 cells/mm3 who are initiated on a nevirapine based 
regimen have been demonstrated to have a 12-fold increased risk of developing 
severe hepatotoxicity [11], while their male counterparts have a 5-fold risk of severe 
hepatotoxicity if their CD4 counts exceed 500 cells/mm3  [8]. However, some studies 
failed to demonstrate an association between a high CD4 count and the 
development of severe hepatotoxicity in female patients [37-38].This could have 
been due to different study populations as the studies which demonstrated an 
association were mainly done in populations with a high HIV/HCV co-infection. 
This relationship is of important significance in sub-Saharan Africa since most 
antiretroviral programs use nevirapine-based regimens.  
 
High HIV infection rates and weak health-care systems in sub-Saharan Africa have 
been noted to be driving the tuberculosis epidemic [19, 39]. The fact that 
tuberculosis is the commonest opportunistic infection in our setting is of great 
significance as co-administration of tuberculosis treatment and HAART is inevitable. 
Studies conducted in South Africa have demonstrated that co-administration of anti-
tuberculous drugs in patients on HAART increases the risk hepatotoxicity [26, 40]. 
 
Higher levels of baseline Alanine aminotransferase (ALT) have been associated with 
the development of severe hepatotoxicity in patients on HAART [11, 21, 29, 37]. The 
lack of an association between baseline ALT levels and development of 
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hepatotoxicity in other studies [16-17] could be due to methodological inadequacies 
such as bias and poor sample size.  
 
Heavy alcohol consumption has been demonstrated to increase the risk of 
hepatotoxicity in patients initiated on antiretroviral therapy [16, 41]. Paucity of 
information on alcohol as a possible risk factor in many studies could be attributed to 
the crude measure of alcohol use by investigators. It may also be due to the fact that 
fewer studies collected this type data. 
 Advancing age has also been associated with increased risk of hepatotoxicity in 
patients on antiretroviral treatment [16].  
 
Rapid CD4 count increases while on HAART have been postulated to increase the 
risk of developing hepatotoxicity in some studies. A prospective cohort study in the 
United States of America (USA) demonstrated that a CD4 count increase of more 
than 50 cells/mm3 in a 25 week follow-up period increased the risk of hepatotoxicity 
by 3.6 times [18]. 
 
The debate over potential gender differences in risk of developing hepatotoxicity 
while on HAART is ongoing and the results are conflicting. Some studies have 
demonstrated an increased risk of hepatotoxicity in female patients compared to 
their male counterparts [42-43].The association was stronger in females with a body 
mass index (BMI) of less than 18.5 [22]. Some studies failed to demonstrate such 
association [44-45]. A common weakness of these studies is that they included a 
relatively small number of women participants and hence were not sufficiently 
powered to detect sex-based differences.   
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Some independent viral, biochemical and haematological risk factors for HAART-
induced hepatotoxicity have been described in a South African randomised, double-
blinded multicentre trial. These factors included a protein serum level of less than 
35g/L, a mean corpuscular volume greater than 85fL, a plasma HIV-1 RNA load of 
less than 2000copies/ml and a lactate dehydrogenase level of less than 164 IU/L 
[22]. 
      
           Limitations of previous studies 
Besides the lack of a standard definition of hepatotoxicity, most of the studies looking 
at the factors associated with hepatotoxicity in patients on HAART were done in 
resource rich settings on European cohorts [3, 8, 11-18]. A few studies have looked 
at African cohorts in resource poor settings [19-22]; however, these settings face 
challenges of limited regimen options and poor laboratory facilities to monitor 
patients adequately.  
 
Different patient follow-up time to the development of hepatotoxicity also makes it 
difficult to extrapolate different study findings to our setting. Not all studies 
considered the same possible predictors of hepatotoxicity and hence confounding 
could have played a factor in some of the observed associations or lack of it. 
 
There is limited data from resource limited cohorts especially in Sub-Saharan Africa. 
Hence this research project to investigate the incidence of and risk factors for 
hepatotoxicity in patients initiated on HAART at an antiretroviral rollout-clinic in 
Johannesburg, South Africa.  
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Definition of terms 
 
Alanine aminotransferase (ALT): A liver enzyme that generally indicates liver 
damage (hepatotoxicity) when found in blood in elevated quantities. Normal levels 
are usually less than or equal to 40 International Units per litre (I.U/L). 
 
Highly Active Antiretroviral Therapy (HAART): The use of three or more anti-HIV 
drugs in order to decrease viral multiplication and progress of HIV disease. 
 
Efavirenz-based HAART: Use of stavudine, lamivudine and efavirenz drugs for 
managing HIV/AIDS  
 
Nevirapine-based HAART: Use of stavudine, lamivudine and nevirapine drugs for 
managing HIV/AIDS 
 
Body Mass Index (BMI): It is an anthropometric measure which is calculated by 
dividing an individual’s weight (in kilograms) by the square of height (in metres) 
 
 
Study Objectives 
 
          General Objective 
To determine the incidence and factors associated with severe hepatotoxicity 
following initiation of antiretroviral therapy in a South African cohort 
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Specific objectives 
 To describe the baseline characteristics of patients at initiation of 
antiretroviral therapy  
 To determine the incidence of severe hepatotoxicity within 12 months  of  
initiating antiretroviral therapy 
 To investigate factors associated with incident hepatotoxicity in patients 
initiated on antiretroviral therapy  
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CHAPTER TWO 
 
 
METHODOLOGY 
 
Introduction: This chapter outlines the study design and methods used in the 
report. The study population and selection of participants is described. Details of 
data collection and management are described. Variables used for analyses are 
outlined. The definition of severe hepatotoxicity is explained and the chapter 
concludes with an outline of the data analysis plan and ethical considerations.  
 
 
Study Design 
The study design is a cohort study. Secondary analysis of prospectively collected 
cohort data among patients initiating HAART at Themba Lethu Clinic between 1 April 
2004 and 30 June 2009 was done. 
 
Study Site 
Themba Lethu clinic is one of the largest urban antiretroviral sites annexed to Helen 
Joseph Hospital, a teaching public hospital situated in Johannesburg, South Africa. It 
started operating in April 2004 following the antiretroviral treatment roll-out program 
initiated by the South African government. From the time of its inception, the clinics’ 
enrolment has been increasing considerably. Currently, the clinic has an enrolment 
of over 25000 patients in care and provides HAART to over 16000 of these patients 
according to the National Department of Health (DoH) guidelines [46]. Even though 
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the clinic enrols and follow-up patients from Gauteng Province and beyond, the 
majority of its clients are mainly of urban origin.    
        
Study Population 
The study population consisted of all HIV positive individuals started on HAART at 
Themba Lethu Clinic from 1 April 2004 to 30 June 2009. 
 
Study Sample 
No sampling was done. 9764 HIV positive adults initiated on HAART at Themba 
Lethu Clinic between 1 April 2004 and 30 June 2009 meeting the following criteria 
were included in the analysis:   
        Inclusion criteria 
 Patients started on first line HAART at Themba Lethu Clinic between 1 
April 2004 and 30 June 2009. 
 Patients with ALT results at baseline and at least once after initiating 
HAART 
 HAART naïve patients 
 Adults aged 18 years and older at time of HAART initiation 
Exclusion Criteria 
 Patients with no baseline ALT levels 
 Pregnant women because they are initiated on HAART according to 
different guidelines and on different regimens. The haemodilution effect 
of pregnancy can affect laboratory results.  
 Baseline ALT ≥ 104 I.U/L 
 Viral load < 400 copies/mm3 
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 Clients aged less than 18 years  
 Clients on other HAART regimens other than the 6 possible first line 
combinations 
 
Data sources 
The data used in the study was recorded at the patient’s initial and subsequent clinic 
visits. Data is stored on an electronic patient management and decision support 
system called Therapy Edge-HIV TM. The database is managed and maintained by 
the non-profit organisation, Right to Care (RTC). Data are entered directly into the 
system by clinical staff during patient visits.  Demographic and contact details of 
clients are recorded at the initiation visit. Patients’ vital measurements, weight and 
any symptoms or new diagnoses made on each subsequent visit to the clinic are 
also recorded and entered into Therapy Edge-HIV TM. Additionally, results of blood 
tests for ALT, CD4 count, haemoglobin and other laboratory tests are measured at 
each scheduled clinic visit and entered into the database. 
The data used in analysis was obtained from variables already captured on Therapy    
Edge-HIVTM database. The names of patients were removed from the data set and 
replaced with unique study numbers before the data was provided for analysis. 
 
Study variables 
Outcome variable 
The risk of developing severe hepatotoxicity while on HAART with different potential 
risk factors (exposure variables) is estimated. Severe hepatotoxicity (the primary 
study outcome) was defined as either grade 3 or 4 elevation in ALT level within the 
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first twelve months of initiating antiretroviral treatment in patients with normal 
baseline ALT levels.  
We followed study participants for 12 months from the day of initiating the first line 
HAART regimen. According to the National Department of Health (DoH) guidelines, 
patients are usually started on one of the following first line regimens: 
stavudine+lamuvidine+efavirenz, stavudine+lamuvidine+nevirapine, 
zidovudine+lamuvidine+efavirenz and zidovudine+lamuvidine+nevirapine [46].   
Following initiation of therapy, liver function was assessed two weekly for the first 
month, at 8 weeks then 6 monthly for those clients on nevirapine, whereas clients on 
EFV had their liver function assessed at one month, and thereafter every six months 
following HAART initiation. A patient was regarded as having developed the event of 
interest if ALT was found to be elevated at these or any other clinically indicated 
visits. 
 
Exposure variables 
     Socio-demographic variables 
 Age, 
 Gender  
 alcohol intake status 
 smoking status 
 
Clinical variables  
 baseline haemoglobin (Hb) level 
 clinical HIV Stage  
 HAART regimen 
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 diagnosis of tuberculosis at time of initiating HAART 
 baseline body mass index (BMI) 
 baseline CD4 count, 
 baseline ALT levels 
Data management and cleaning  
Observations where individuals were pregnant, under 18 years of age or on other 
regiments than the standard first line HAART were dropped from the data set. 
The de-identified nature of the dataset, made it impractical to verify values which 
appeared unrealistic and therefore these values were set to missing. The following 
variables had biologically implausible values in the dataset. The action taken was 
that implausible values were excluded.  
 BMI (values between 15 kg/m2 and 50 kg/m2 were taken as plausible) 
 Haemoglobin (values between 1g/dL and 18g/dL were taken as plausible) 
 Age at initiation (values between 18 years and 90 years were considered) 
New variables were generated; data was coded and recorded to allow for 
appropriate analysis in order to meet the study objectives. 
 
Data processing methods and data analysis 
Statistical analysis was done using STATA version 11.0 (STATA corporation, college 
station, Texas, USA). 
 
Descriptive statistics (Table 1) were used to summarize the baseline characteristics 
of the cohort overall and by presence and absence of severe hepatotoxicity. 
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A comparison of the characteristics of the overall cohort and individuals excluded 
from the study on the basis of absent baseline ALT results is given in Table 2. 
 
The overall incidence rate of severe hepatotoxicity was calculated. Incidence rates at 
specific time periods were determined and given in Table 3. Incidence rates by 
HAART regimen and baseline ALT category were also calculated and presented. 
 
Time-to-event analysis was performed using survival techniques, including Kaplan-
Meier estimates, log rank test and Cox proportional hazards models. 
 
Univariate Cox proportional hazard models were built to determine the crude 
estimates between potential risk factors and severe hepatotoxicity. 
Biological plausibility and change in estimate method were used to select variables 
for the multivariate model. Factors known to be biologically associated with severe 
hepatotoxicity post-HAART initiation were chosen a priori, together with the factor 
with the most significant estimate in univariate analysis to be the initial model. A 
possible risk factor which changed the estimate in the initial model by more than 
10% was selected for the final adjusted model.  
Final model adequacy and assumptions were tested for and presented in the 
appendix section. Interactions between exposure variables was tested for and 
reported.  
The 5% significance level was used for all statistical significance tests in the report. 
 
Sensitivity and specificity of clinical diagnosis of severe hepatotoxicity (with 
laboratory diagnosis as the gold standard) was calculated. Correlation between 
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clinical diagnosis of severe hepatotoxicity and biochemical diagnosis was 
ascertained by calculating the kappa (қ) statistic.  
 
Ethical considerations 
The study was conducted according to the Standard Operation Procedure (SOP) of 
the Clinical HIV Research Unit governing the analysis of data from the Themba 
Lethu Clinical Cohort (appendix A) which includes obtaining the approval of the 
research protocol by the University of the Witwatersrand Committee for Research on 
Human Subjects (Medical) (appendix B) and permission to conduct the study from 
the Chief Executive Officer of Helen Joseph Hospital where the Themba Lethu Clinic 
is based (appendix C). Names of patients were removed from the dataset and 
replaced by unique identifiers by personnel at the site before analysis. This was 
done to respect the privacy of the patients who provided the information 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
CHAPTER THREE 
 
 
 
RESULTS 
 
Introduction: In this chapter, the results of the research report are presented by first 
describing how the study sample was obtained. The overall baseline characteristics 
of the study participants and characteristics stratified by severe hepatotoxicity post-
HAART are outlined next. Incidence rates of severe hepatotoxicity are considered. 
Factors associated with the development of severe hepatotoxicity in this cohort are 
investigated and presented. The chapter concludes by investigating the correlation 
between clinicians’ and laboratory diagnosis of severe hepatotoxicity.    
  
Study participants 
Since its inception, Themba Lethu Clinic has enrolled 27 941 patients in care. A total 
of 13 983 of these patients were started on HAART between 1 April 2004 and 30 
June 2009. The remainder of the enrolled patients were either not on HAART or 
were on HAART but enrolled outside the study period. Of the 13 983 patients who 
started HAART during the study period, 9764 eligible patients were included in the 
analysis according to the flow diagram in Figure 1.  
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Determination of study sample and clients at the end of the study period 
 
  
                                                                               1057 with a viral load less than 400 copies/ml 
    102 pregnant participants excluded 
          63 participants under the age of 18 were 
excluded 
1231 excluded because there were on other 
regimens other than the 6 possible first line 
combinations 
1555 participants excluded because they had 
no baseline ALT 
203 participants excluded with ALT ≥ 104 at 
initiation of HAART 
8 participants excluded who had date of 
initiation later than date of confirmed lost to 
follow-up 
 
 
  1 984 patients were lost to follow-up 
                                                                                        
   2217 were either transferred to other facilities 
or died 
 
 
 
Figure 1:   Flow chart showing selection of study participants and patients remaining on study at the 
end of the study period 
13 983 patients started on 
HAART between 01/04/04 
and 30/06/09  
 
9 764 (study sample) 
5 563 clients at the end 
of the study period 
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After applying the inclusion and exclusion criteria (see Figure 1 above), 9 764 
patients were left for analysis. Out of the 9 764 patients, 1 984 (20.3 %) were lost to 
follow-up and 2 217 (22.7 %) were either transferred to other facilities or died during 
the follow-up period.  
Baseline characteristics of study participants 
The baseline characteristics (demographic, clinical and social) of the overall cohort, 
as well as the baseline characteristics compared by severe hepatotoxicity post 
HAART initiation are presented in Table 1 below. The categorisation of severe 
hepatotoxicity was based on the development or absence of new hepatic disease 
following HAART initiation. 
 
Table 1: Baseline characteristics of the Themba Lethu Clinic cohort  
 
   Severe hepatotoxicity post 
HAART initiation 
                                                                             
Characteristics     
 
N 
Overall 
n ,% 
No 
n ,% 
Yes 
n ,% 
Age in years  9764 37.4(8.7)  ٭  37.4(8.7)  ٭  35.4(7.0)  ٭  
Age Category (in years)          
                  < 25 years 
                  25-34 years 
                  35-44 years 
                  >45 years  
9764  
467(4.8) 
3800(38.9) 
3689(37.8) 
1808(18.5) 
 
461(4.8) 
3765(38.9) 
3648(37.7) 
1800(18.6) 
 
6(6.6) 
35(38.9) 
41(45.6) 
8(8.9) 
Gender                  
             Female 
             Male  
9764  
6113(62.6) 
3651(37.4) 
 
6061(62.6) 
3613(37.4) 
 
52(57.8) 
38(42.2) 
Smoking  Status              
                         No 
                         Yes 
9764  
8730(89.4) 
1034(10.6) 
 
8652(89.4) 
1022(10.6) 
 
78(86.7) 
12(13.3) 
Alcohol intake Status        
                        Yes 
                        No 
9764  
8669(88.8) 
1095(11.2) 
 
8588(88.8) 
1086(11.2) 
 
81(90.0) 
9(10.0) 
BMI Category (in kg/m
2
)  8510    
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                       Normal (18.5 - 25) 
                       Underweight (<18.5) 
                       Overweight (>25)   
4886(57.4) 
1819(21.4) 
1805(21.2) 
4841(57.4) 
1801(21.4) 
1788(21.2) 
45(56.3) 
17(21.2) 
18(22.5) 
Baseline Hemoglobin (in g/dL)  9764 11.4(2.2)٭ 11.4(2.2)  ٭  11.7(2.4)  ٭  
Baseline Hemoglobin Category (in g/dL)          
                                            ≥8.5  
                                            <8.5                                      
9764  
8875(90.9) 
889(9.1) 
 
8793(90.9) 
881(9.1) 
 
82(91.1) 
8(8.9) 
Baseline CD4 count (in cells/mm
3
) 9204 80(29-149) † 81(29-149) † 57(22-126) † 
CD4 count Category (in cells/mm
3
) 
                                        <50 
                                        50-100 
                                        100-200  
                                        >200                            
9204  
3385(36.8) 
1917(20.8) 
3133(34.0) 
769(8.4) 
 
3349(36.7) 
1897(20.8) 
3110(34.1) 
763(8.4) 
 
36(42.3) 
20(23.5) 
23(27.1) 
6(7.1) 
Baseline ALT      (in IU/L) 9764 23(16-34) † 23(16-34) † 30(20-41) † 
ALT baseline Category (in IU/L) 
                          <40 
                          >40 
9764  
7989(81.8) 
1775(18.2) 
 
7222(81.9) 
1752(18.1) 
 
67(74.4) 
23(25.6) 
History of Tuberculosis        
                              No 
                              Yes            
9758  
7849(80.4) 
1909(19.6) 
 
7783(80.5) 
1886(19.5) 
 
66(74.2) 
23(25.8) 
HAART regimen   
                   Efavirenz-based  
                   Nevirapine-based 
9764  
8962(91.8) 
802(8.2) 
 
8887(91.9) 
787(8.1) 
 
75(83.3) 
15(16.7) 
HIV Stage   
                           1 
                           2 
                           3 
                           4 
7830  
3142(40.1) 
1243(15.9) 
2570(32.8) 
875(11.2) 
 
3109(40.1) 
1234(15.9) 
2548(32.9) 
861(11.1) 
 
33(42.3) 
9(11.5) 
22(28.2) 
14(18.0) 
٭Baseline Haemoglobin and Age at initiation was described using means and standard deviations as 
there were fairly normally distributed (see appendix D)  
†medians and interquartile range used as the data was not normally distributed (see appendix E) 
 
Characteristics of the overall cohort 
The average age of the overall cohort was 37.4 years (std 8.4 years). The majority of 
the patients were aged between 25 and 44 years of age. The number of female 
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patients was about double that of their males. About 10% of the overall cohort 
smoked while a similar proportion of participants reported taking alcohol.  
20% of the individuals were considered underweight, while another 20% was 
considered overweight. 
20% of the overall cohort had a diagnosis of tuberculosis at the time of initiating 
HAART. The majority of the participants were initiated on an efavirenz-based 
regimen, a regimen recommended by the Department of Health (DoH) guidelines for 
initiating antiretroviral therapy in treating naïve patients [46]. 8.2% of the overall 
cohort was initiated on a nevirapine-based regimen. The median baseline ALT level 
of the overall cohort was 28 I.U/L (IQR 16-34); with 82 % of individuals with ALT < 40 
I.U/L. 9.1% of the cohort had a baseline haemoglobin < 8.5g/dL. The median 
baseline CD4 count at initiation of HAART for this cohort was 80 cells/ mm3 (IQR 29-
149) which is much lower than the DoH CD4 cut off for initiating HAART of 200 cells/ 
mm3 [46]. 
 
      Characteristics by severe hepatotoxicity post HAART initiation 
Individuals who developed severe hepatotoxicity had a mean age of 35.4 years (std 
7.0 years), two years younger than individuals who did not develop severe 
hepatotoxicity who had a mean age of 37.4 (std 8.7 years).The mean baseline 
haemoglobin level of individuals who developed severe hepatotoxicity was similar to 
the mean baseline haemoglobin level for individuals without severe hepatotoxicity. 
There were also no obvious differences in the Body Mass Index of individuals who 
developed severe hepatotoxicity and those ones who did not. 
Individuals who developed severe hepatotoxicity had a lower median baseline CD4 
count (57 cells/mm3; IQR 22-126) compared to individuals who did not have severe 
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hepatotoxicity (81 cells/mm3; IQR 29-149). The median baseline ALT level was 
higher in clients with severe hepatotoxicity (30 I.U/L; IQR 20-41) compared to those 
individuals without the outcome of interest (23 I.U/L; IQR 16-34). 
About a fifth (18.0%) of the individuals who developed severe hepatotoxicity had 
stage 4 HIV infection while 11% of individuals who did not have severe 
hepatotoxicity had stage 4 HIV infection.  
 
        Characteristics of excluded individuals on the basis of missing baseline 
ALT results 
Below (Table 2), is a comparison of the baseline characteristics of the overall cohort 
and the individuals excluded from the study on the basis of missing baseline ALT 
results.   
 
Table 2:  Comparison of baseline characteristics of the overall cohort and 
characteristics of the excluded individuals due to missing ALT results 
 
                                                                    
 
Characteristic     
 
 
N 
Study 
participants 
  
n ,% 
 
 
 
N 
Excluded individuals 
with missing 
baseline ALT 
n ,% 
Age (in years)  9764 37.4(8.7)  ٭  1555 37.1(8.5)  ٭  
Age Category (in years)          
                  < 25 years 
                  25-34 years 
                  35-44 years 
                  >45 years  
9764  
467(4.8) 
3800(38.9) 
3689(37.8) 
1808(18.5) 
1555  
82(5.3) 
635(40.8) 
541(34.8) 
297(19.1) 
Gender                  
             Female 
             Male  
9764  
6113(62.6) 
3651(37.4) 
1555  
1012(65.1) 
543(34.9) 
Smoking  Status              
                         No 
                         Yes 
9764  
8730(89.4) 
1034(10.6) 
1555  
1433(92.2) 
122(7.8) 
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Alcohol intake Status        
                        Yes 
                         No 
9764  
8669(88.8) 
1095(11.2) 
1555  
1405(90.4) 
150(9.6) 
BMI Category (in kg/m
2
)  
                       Normal (18.5 - 25) 
                       Underweight (<18.5) 
                       Overweight (>25)   
8510  
4886(57.4) 
1819(21.4) 
1805(21.2) 
557  
331(59.4) 
115(20.7) 
111(19.9) 
Baseline Hemoglobin (in g/dL)  9764 11.4(2.2)  ٭  1555 10.8(2.5)  ٭  
Baseline Hemoglobin Category  
(in g/dL)                ≥8.5                                                
<8.5                                       
9764  
8875(90.9) 
889(9.1) 
1555  
1497(96.3) 
58(3.7) 
Baseline CD4 count (in cells/mm
3
) 9204 80(29-149) † 499 84(34 - 163) † 
CD4 count Category (in cells/mm
3
) 
                        <50 
                        50-100 
                        100-200  
                        >200                            
9204  
3385(36.8) 
1917(20.8) 
3133(34.0) 
769(8.4) 
499  
169(33.9) 
111(22.2) 
152(30.5) 
67(13.4) 
History of Tuberculosis        
                              No 
                              Yes            
9758  
7849(80.4) 
1909(19.6) 
1555  
1322(85.0) 
233(15.0) 
HAART regimen   
                   Efavirenz-based  
                   Nevirapine-based   
9764  
8962(91.8) 
802(8.2) 
1555  
1263(81.2) 
292(18.8) 
HIV Stage   
                           1 
                           2 
                           3 
                           4 
7830  
3142(40.1) 
1243(15.9) 
2570(32.8) 
875(11.2) 
548  
219(40.0) 
80(14.6) 
178(32.5) 
71(12.9) 
٭Baseline Haemoglobin and Age at initiation was described using means and standard deviations as 
there were fairly normally distributed (see appendix D) 
†medians and interquartile range used as the data was not normally distributed (see appendix E) 
 
The characteristics of the 1555 individuals who were excluded from the study sample 
looked very similar to those of the overall cohort as can be seen from Table 2 above. 
Besides differences in HAART regimen and Haemoglobin categories, the excluded 
individuals looked fairly similar to the overall cohort. The excluded group had more 
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than double the proportion of individuals on a nevirapine-based regimen compared 
to the study participants. 9.1% of individuals in the study sample were anaemic 
compared to only 3.1% in the excluded group.   
 
 
Incidence of severe hepatotoxicity 
Overall incidence rate of severe hepatotoxicity 
Out of 9764 participants followed up for a total of 8424 person-years (p-yrs), with a 
median follow-up time of 1 year, 90 cases of severe hepatotoxicity were observed, 
corresponding to an overall incidence rate of 10.7 (95% CI: 8.7 – 13.1) cases per 
1000 p-yrs of follow-up.  
Below (Figure 2), is a Kaplan-Meier plot showing time to severe hepatotoxicity in the 
first year of initiating HAART. 
                             
Figure 2:  Kaplan-Meier plot showing cumulative hazard estimates for severe 
hepatotoxicity post-HAART 
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The above Kaplan-Meier plot indicates the overall risk of developing severe 
hepatotoxicity among the study participants. The cumulative hazard estimates of the 
cohort, including a risk table showing the numbers at risk for selected follow-up times 
are also shown. 
 
      Period incidence rates of severe hepatotoxicity 
The table below (Table 3) shows the overall period incidence rates for severe 
hepatotoxicity at specified time periods after initiation of HAART. 
 
Table 3 depicts that the greatest risk of developing severe hepatotoxicity occur in the 
first two months post-HAART initiation with an incidence rate of 26.4 per 1000 p-yrs 
of follow-up time. The incidence rate decreases with time after initiation of HAART to 
5.1 per 1000 p-yrs of follow-up between 6 to 12 months 
Table 3: Overall period incidence rates for severe hepatotoxicity at specific time 
periods post-HAART initiation 
 
 
Time after 
HAART 
initiation 
All cases of 
severe 
hepatotoxicity 
n (%)  
Period incidence 
(per 1000 p-yr) 
 
(CI) 
0  - 2 months 42 (46.7) 26.4 (19.5-35.7) 
2 – 4 months 15 (16.7) 9.9 (5.9-16.3) 
4 – 6 months 13 (14.4) 9.2 (5.3-15.9) 
6 –  12 months 20 (22.2) 5.1 (3.3-8.0) 
 
 
        
Crude estimates of risk factors for severe hepatotoxicity 
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1. Initiating HAART regimen 
Incidence rates of severe hepatotoxicity by HAART regimen 
Of the 802 individuals on a nevirapine-based regimen with a total follow-up time of 
712 p-yrs, 15 cases developed severe hepatotoxicity. This translates to an incidence 
rate of 21.1(95% CI: 12.7 – 34.9) cases per 1000 p-yrs of follow-up.  
8962 individuals on an efavirenz-based regimen were followed up for a total of 7708 
p-yrs. 75 of these participants developed severe hepatotoxicity corresponding to an 
incidence rate of 9.7 (95% CI: 7.8 – 12.1) cases per 1000 p-yrs of follow-up, which is 
less than half the incidence rate of a nevirapine-based regimen.   
 
       Cumulative hazard estimates for severe hepatotoxicty by HAART regimen 
Of the 8962 individuals on an efavirenz-based regimen, 75 (0.8%) developed severe 
hepatotoxicity compared with 15 (1.9%) of the 802 individuals on nevirapine. Figure 
3 below shows the cumulative hazard estimates of severe hepatotoxicity by HAART 
regimen and a risk table at selected time periods post HAART initiation.  
 
From the Kaplan-Meier plot below (Figure 3), patients on a nevirapine-based 
regimen have greater hazard of developing hepatotoxicity after initiating HAART 
compared to their counterparts on an efavirenz-based regimen. The log rank test for 
equality of hazard was (χ2 = 8.04, p = 0.0046). 
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Figure 3: Kaplan-Meier plot showing cumulative hazard estimates of hepatotoxicity 
by HAART regimen 
 
2. Baseline laboratory results  
2.1. Baseline ALT category      
          Incidence rates of severe hepatotoxicity by baseline ALT category 
Out of 7989 individuals with a baseline ALT result less than 40 I.U/L with 6955 p-yrs 
of total follow-up time, 67 cases of severe hepatotoxicity occurred corresponding to 
an incidence rate of 9.6 (95% CI: 7.6 – 12.2) cases per 1000 p-yrs of follow-up.  
However, individuals with an ALT result greater than 40 I.U/L at baseline had an 
incidence rate of 15.7 (95% CI: 10.4 – 23.5) cases  per 1000 p-yrs of follow up (23 
out of 1775 cases with a follow-up time of 1465 p-yrs) which is double the rate in 
individuals with an ALT result less than 40 I.U/L.     
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29 
 
           Cumulative hazard estimates of severe hepatotoxicity by baseline ALT 
category 
Of the 7989 individuals with a baseline ALT less than or equal to 40 I.U/L, 67 (0.8%) 
developed severe hepatotoxicity compared with 23 (1.3%) of the 1775 individuals 
with a baseline ALT greater than 40 I.U/L.  Figure 4 below shows the cumulative 
hazard estimates of severe hepatotoxicity by ALT category and a risk table at 
selected time periods post HAART initiation.  
 
 
         
Figure 4:  Kaplan-Meier plot showing cumulative hazard estimates of severe 
hepatotoxicity by baseline ALT levels 
 
Individuals who had a baseline ALT result of 40 I.U/L or more had increased risk of 
developing hepatotoxicity compared to those with an ALT result less than 40 I.U/L. 
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The log-rank test for equality of hazard functions showed that there is a statistically 
significant difference in hazards for the two groups (χ2 = 3.90, p = 0.0482). 
 
2.2. Baseline CD4 count category 
           Cumulative hazard estimates for severe hepatotoxicity by CD4 count 
category 
Of the 3385 individuals with a baseline CD4 count less than 50, 36 (1.1%) developed 
severe hepatotoxicity compared with 20 (1.0%) of the 1917 individuals with a CD4 
count between 50 and 100; 23 (0.7%) of the 3133 individuals with a CD4 count 
between 100; and 200 and 6 (0.8%) of the 769 individuals with a CD4 count greater 
than 200. Figure 5 below shows the cumulative hazard estimates of severe 
hepatotoxicity by CD4 count category and a risk table at selected time periods post 
HAART initiation.  
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Figure 5:  Kaplan-Meier plot showing cumulative hazard estimates of hepatotoxicity   
by CD4 count category 
 
 
The above Kaplan Meier plot (Figure 6) shows that all the CD4 count categories 
have similar risk of developing severe hepatotoxicity post-HAART initiation. The log-
rank test for equality of hazard functions between CD4 count categories showed that 
there is no statistically significant difference in hazards for the different categories at 
α=5% (Log rank test: χ2 = 3.34, p = 0.3426). 
 
3. Demographic features 
3.1. Gender 
          Cumulative hazard estimates for severe hepatotoxicity by gender 
Of the 6113 female participants, 52 (0.9%) developed severe hepatotoxicity 
compared with 38 (1.0%) of the 3651 males. Figure 4 below shows the cumulative 
hazard estimates of severe hepatotoxicity by gender and a risk table at selected time 
periods post HAART initiation.  
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Figure 6:  Kaplan-Meier plot showing cumulative hazard estimates of severe 
hepatotoxicity by gender 
 
From the above Kaplan Meier plot (Figure 5), both genders have similar risk of 
developing severe hepatotoxicity post HAART initiation. The log-rank test for equality 
of hazard functions between males and females showed that there is no difference in 
hazards for the two groups at α=5% (Log rank test: χ2 = 1.07, p = 0.3001).  
 
3.2. Age Category 
          Cumulative hazard estimates for severe hepatotoxicty by age category 
Of the 467 individuals aged less than 25 years, 6 (1.3%) developed severe 
hepatotoxicity compared with 35 (0.9%) of the 3800 individuals aged between 25 
and 34; 41 (1.1%) of the 3689 individuals aged between 35 and 44; and 8 (0.4%) of 
the 1808 individuals older than 45.  Figure 6 below shows the cumulative hazard 
estimates of severe hepatotoxicity by age category and a risk table at selected time 
periods post HAART initiation.  
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Figure 7:  Kaplan-Meier plot showing cumulative hazard estimates of hepatotoxicity 
by age category 
 
The Kaplan Meier plot above (Figure 6) shows that all the age categories have 
similar risk of developing severe hepatotoxicity post-HAART initiation. However, the 
estimates are imprecise. The log-rank test for equality of hazard functions between 
the age categories showed that there is no statistically significant difference in 
hazards for the age categories at α=5% (Log rank test: χ2 = 6.54, p = 0.0881).       
   
Estimating adjusted risk factors for severe hepatotoxicity  
Risk factors for severe hepatotoxicity after initiation of HAART were estimated using 
Cox proportional hazard models. The hazard ratios for the univariate and multivariate 
models are presented in Table 4 below. 
 
        Univariate analysis 
In the unadjusted Cox proportional hazard regression model, age at initiation and 
HAART regimen were significantly associated with severe hepatotoxicity as depicted 
in Table 4 below.  
For every one year increase in age of an individual, there was a 3% reduction in the 
hazard ratio for developing severe hepatotoxicity. Individuals started on a nevirapine-
based regimen had more than double the hazard of developing severe hepatotoxicity 
compared to their counterparts who were started on an efavirenz-based regimen 
(HR = 2.19; 95%CI = 1.26 – 3.81; p = 0.006). The hazard for developing severe 
Time  0 2 4 6 8 12 
n at risk       
< 25 467 449 433 389 370 353 
25 – 35 3800 3618 3483 3197 3080 2901 
35 – 45 3689 3517 3390 3109 3005 2831 
> 45  1808 1715 1654 1518 1447 1360 
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hepatotoxicity was 60% higher for individuals with a baseline ALT > 40 I.U/L when 
compared to individuals with a baseline ALT < 40 I.U/L. This association was 
imprecise at α = 5% (HR = 1.60; 95%CI = 1.00 – 2.48; p = 0.05). 
 
         Multivariate analysis 
Age, gender and CD4 count category were chosen up front (a priori) to be included 
in the final multivariate model on the basis of biological plausibility. The initial model 
had the above factors included and HAART regimen (the most significant factor in 
unadjusted analysis). The change in estimate method was used to arrive on the final 
model. Using this method, possible risk factors were added to the initial model one 
variable at a time. The hazard ratio obtained at each step was compared with the 
one generated from the previous step. Only those factors which changed the 
estimates by more than 10% were included in the final model presented in Table 4 
below. 
 
In the adjusted model, HAART regimen remained significantly associated with 
development of severe hepatotoxicity following HAART initiation at 5% significant 
level. The estimates for baseline ALT category suggested an increased risk for 
severe hepatotoxicity, though imprecise. 
 
 Table 4: Factors associated with severe hepatotoxicity after initiating HAART 
                                                                             
Characteristics     
Univariate 
Analysis 
HR (95% CI) 
 
p-value 
Multivariate 
Analysis 
HR (95% CI) 
 
p-value 
Age (in years)  0.97(0.95 – 0.99)  0.032 0.98 (0.95 – 1.00) 0.078 
Age Category (in years)          
                  < 25 years 
 
1 
 
 
  
35 
 
                  25-34 years 
                  35-44 years 
                  >45 years  
0.71 (0.30 – 1.70)  
0.86 (0.37 – 2.03)  
0.34 (0.12 – 0.99)  
0.447 
0.731 
0.049 
Gender                  
             Female 
             Male  
 
1 
1.25 (0.82 – 1.89)  
 
 
0.301 
 
1 
1.30 (0.84 – 2.03)  
 
 
0.243 
Smoking  Status              
                         No 
                         Yes 
 
1 
1.28 (0.69 – 2.34)  
 
 
0.433 
  
Alcohol intake Status        
                        No 
                        Yes 
 
1 
0.86 (0.43 – 1.71)  
 
 
0.659 
 
 
 
 
Baseline Hemoglobin (in g/dL)  
 
0.05 (0.95 – 1.15)  
 
0.345 
  
Baseline Hemoglobin Category  
(in g/dL)          
                                 ≥8.5  
                                 <8.5                                        
 
 
1 
1.07 (0.52 – 2.21)  
 
 
 
0.857 
 
 
 
CD4 count Category (in cells/mm
3
) 
                        <50 
                        50-100 
                        100-200  
                        >200                            
 
1 
0.93 (0.54 – 1.60)  
0.64 (0.38 – 1.08)  
0.67 (0.28 – 1.60)  
 
 
0.784 
0.094 
0.368 
 
1 
0.99 (0.57 – 1.71)  
0.68 (0.40 – 1.16)  
0.70 (0.29 – 1.67)  
 
 
0.962 
0.161 
0.418 
ALT baseline Category (IU/L) 
                          <40 
                          >40 
 
1 
1.60 (1.00 – 2.58)  
 
 
0.050 
 
1 
1.62 (1.00 – 2.65)  
 
 
0.052 
History of Tuberculosis        
                              No 
                              Yes            
 
1 
1.45 (0.90 – 2.33)  
 
 
0.126 
  
HAART regimen   
                   Efavirenz-based  
                   Nevirapine-based  
 
1 
2.19 (1.26 – 3.81)  
 
 
0.006 
 
1 
2.07 (1.13 – 3.79)  
 
 
0.019 
HIV Stage   
                           1 
                           2 
                           3 
                           4 
 
1 
0.70 (0.33 – 1.46)  
0.84 (0.49 – 1.44)  
1.68 (0.90 – 3.13)  
 
 
0.338 
0.530 
0.106 
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The hazard of severe hepatotoxicity within the first year of initiating HAART was 2.07 
times higher in individuals on a nevirapine-based regimen compared to those on an 
efavirenz-based regimen after adjusting for baseline ALT, CD4 count, age and 
gender (HR = 2.07; 95%CI = 1.13 – 3.79; p = 0.019).  
Patients with a baseline ALT > 40 I.U/L had a 62% increased hazard of severe 
hepatotoxicity compared to their counterparts with ALT < 40 I.U/L after adjusting for 
HAART regimen, age, CD4 count category and gender. However, the estimates of 
this association was imprecise (HR = 1.62; 95%CI = 1.00 – 2.65; p = 0.052)  
 
Male patients had a 30% increased hazard for severe hepatotoxicity compared to 
females while adjusting for HAART regimen, baseline ALT, age and CD4 count. This 
association was however not statistically significant (HR = 1.30; 95%CI = 0.84 – 
2.03; p = 0.243).  Individuals with CD4 counts between 50 to 100, 100 to 200 and 
above 200 had a 1%, 32% and 30% reduction (respectively) in hazard for severe 
hepatotoxicity compared to those individuals with a CD4 count less than 50 at the 
time of initiating HAART while controlling for HAART, age, ALT and gender. These 
associations were however not statistically significant at the 5% significance level. 
 
HAART regimen, gender and baseline ALT did not violate the proportional hazard 
assumption (appendices F, G & H). However, the stphplot for CD4 count suggests 
minor violation of the proportional hazard assumption as is shown in Appendix F. 
Overally, the whole model did not violate the assumption of proportional hazards (χ2 
= 6.40, p = 0.4935) (appendix H).  
 
Interaction terms were tested for but no significant interactions were detected.  
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Model adequacy was tested for by calculating and plotting Martingale residuals 
against survival time. Appendix 1 suggests that the Cox proportional hazard model 
fits the data poorly. 
 
         Sensitivity analysis 
To investigate the influence of excluding patients with missing baseline ALT results 
from the main analysis, a sensitivity analysis was performed. This was done to see 
whether the exclusion could have biased the hazard ratio estimates presented 
above. 
Firstly, we fit a model including all the individuals with missing baseline ALT values 
assuming that these individuals all had an ALT value of less than 40 I.U/L. The 
estimates for this scenario were then determined. 
We then fit a second model, this time including all the individuals with missing 
baseline ALT values assuming their baseline ALT value was greater than 40I.U/L. 
The estimates for such a situation were also determined.  
The estimates for these two scenarios were then compared to the estimates of the 
main analysis as is depicted in Table 5. 
 
Table 5: Factors associated with severe hepatotoxicity: main analysis (adjusted) and 
sensitivity analyses (adjusted) 
 
 
Characteristic 
Main analysis 
 (adjusted)  
 
HR (95% CI) p-value 
Missing ALT 
included as ALT < 40 
(adjusted) 
HR (95% CI) p-value 
Missing ALT 
included as ALT > 40 
(adjusted) 
HR (95% CI) p-value 
Age (in years)  0.98 (0.95– 1.00)0.078 0.97 (0.95– 0.99)0.043 0.97 (0.95- 0.99)0.042 
Gender                  
       Female 
 
1 
 
1 
 
1 
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       Male  1.30 (0.82– 2.03)0.243  1.37 (0.89- 2.10)0.151 1.37 (0.90- 2.11)0.145 
HAART regimen   
       Efavirenz-based  
       Nevirapine-based  
 
1 
2.07 (1.13– 3.79)0.019 
 
1 
1.98 (1.10- 3.56)0.022 
 
1 
1.96 (1.09- 3.52)0.024 
ALT baseline (IU/L) 
           Less than 40 
           Greater than 40 
 
1 
1.62 (1.00– 2.65)0.052  
 
1  
1.59 (0.98- 2.58)0.059 
 
1 
1.61 (1.03- 2.51)0.037 
CD4 count (cells/mm
3
) 
        Less than 50 
        50 to 100 
       100 to 200  
       Greater than 200                            
 
1 
0.99 (0.57– 1.71)0.962 
0.68 (0.40– 1.16)0.161  
0.70 (0.29– 1.67)0.418  
 
1 
0.95 (0.55–1.65) 0.868 
0.75 (0.45–1.25) 0.276 
0.88 (0.41–1.91) 0.749 
 
1 
0.95 (0.55–1.64) 0.855 
0.75 (0.45–1.25) 0.276 
0.87 (0.40–1.88) 0.720 
    
 
The estimates obtained following conducting sensitivity analyses (Table 5) shows 
that although there are minor deviations from the main analysis results in the two 
scenarios, the confidence intervals of these estimates look very similar. It is thus 
unlikely that excluding records with missing ALT results has biased the estimates in 
the main analysis significantly.    
 
Correlation between recorded clinical diagnosis and laboratory diagnosis of 
severe hepatotoxicity 
Correlation between a recorded diagnosis of hepatotoxicity by attending physicians 
and laboratory diagnosis (as used in the main analysis presented above) was 
calculated using values given in the 2 x 2 table in Table 6 below. A total of 110 
clinical diagnoses of hepatotoxicity were recorded compared to 90 laboratory 
diagnoses. Laboratory diagnosis was used as the gold standard for diagnosis of 
severe hepatotoxicity. Clinicians only diagnosed and recorded 19 out of the 90 
individuals who had biochemically confirmed severe hepatotoxicity. This corresponds 
to a sensitivity of 21.1%.  Of the 9674 individuals without a laboratory diagnosis of 
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severe hepatotoxicity, the attending clinician diagnosis agreed with 9583 of these, 
corresponding to a specificity of 99.1% 
 
Table 6:  2 x 2 table showing number of patients diagnosed clinically and 
biochemically of severe hepatotoxicity at Themba Lethu clinic 
 
  Laboratory diagnosis of severe 
hepatotoxicity 
 
  Yes No Total 
Clinical diagnosis 
of  hepatotoxicity 
Yes 19 91 110 
No 71 9583 9654 
 Total 90 9674 9764 
 
The amount of agreement above chance between Laboratory diagnosis and 
recorded clinical diagnosis of severe hepatotoxicity, (kappa statistic- қ) was 18.2%. 
This means that clinicians correctly diagnosed and recorded whether an individual 
had severe hepatotoxicity or not in only 18.2% of the study participants.  
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CHAPTER FOUR 
 
 
DISCUSSION 
Summary 
The study’s main objectives were to determine the incidence and risk factors for 
severe hepatotoxicity following initiation of HAART in a South African cohort. The 
overall incidence rate of severe hepatotoxicity of 10.7 per 1000 p-yrs of follow-up 
time was substantially lower than incidence rates reported in a South African mine 
[26] and in Italy [30]. HAART regimen was consistently the strongest risk factor 
associated with the development of severe hepatotoxicity after adjusting for age, 
gender, baseline ALT and CD4 count in a multivariate Cox proportional hazard 
regression model. Though imprecise, the estimate for baseline ALT category 
suggested an increased risk of severe hepatotoxicity in individuals with a baseline 
ALT > 40 I.U/L 
 
Baseline characteristics 
The baseline characteristics of the cohort differed from the populations studied in 
previous studies in several aspects.  
 
Participants in an Italian cohort that had a high incidence rate of severe 
hepatotoxicity were all co-infected with HCV [30] whereas participants in our study 
did not have their baseline HCV status evaluated, though it is reportedly low in sub-
Saharan Africa. A study conducted in Malawi reported an HCV prevalence of only 
4.5% [31]. The average CD4 count of this cohort was 80 cells/mm3, a value which is 
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lower than an average CD4 count of 103 cells/mm3 observed in a fairly large and 
representative cohort of 45 000 South African adults at baseline [52].    
There is substantial evidence that suggest that women disproportionately access 
antiretroviral services when compared to men in sub-Saharan Africa, even when the 
higher HIV infection prevalence in females is accounted for [53]. The gender 
distribution of the study sample reflects this pattern. However, studies on cohorts in 
Europe [30], Asia [27] and one other in South Africa [26] had greater proportions of 
male patients compared to this cohort. This is possibly due to the fact that HIV/AIDS 
in other parts of the world is driven mainly by men having sex with men or 
intravenous drug users, whereas the epidemic is mainly driven by heterosexual 
relationships in sub-Saharan Africa. The study on a South African cohort was done 
in a mine setting where the workforce is predominantly male. 
 
The proportion of individuals on an efavirenz-based regimen in this cohort was 
greater than Asian cohorts [27-28] that largely consisted of individuals on a 
nevirapine-based regimen. This difference is largely explained by the fact that 
efavirenz is preferred over nevirapine in first line HAART regimens in areas of high 
tuberculosis prevalence such as sub-Saharan Africa. This is evidenced by the high 
proportion of individuals with a diagnosis of tuberculosis at the time of commencing 
HAART. 
Efavirenz-based regimens are preferred over nevirapine-based ones because 
rifampicin (one of the anti-tuberculous drugs) is a powerful enzyme inducer which 
results in significant reductions in nevirapine blood concentrations in patients on both 
treatments [47]. Furthermore, co-administration of nevirapine and anti-tuberculous 
drugs has been traditionally viewed as highly hepatotoxic. Of the 1909 individuals 
42 
 
who had tuberculosis at the time of initiating HAART, only 34 of them were started 
on a nevirapine-based regimen.  No cases of severe hepatotoxicity were observed in 
individuals who were started on a nevirapine-based regimen while they had a 
diagnosis of tuberculosis. We were therefore unable to assess for effect modification 
between HAART regimen and tuberculosis infection status. 
 
 
Incidence of severe hepatotoxicity 
The cohort had an overall incidence rate of 10.7/1000 p-yrs which is much lower 
than incidence rates reported previously in other studies. For example, one Italian 
cohort that included individuals with HCV/HIV co-infection had an overall incidence 
rate of 177.1/1000 p-yrs. This large difference in incidence could be explained by the 
fact that HCV infection leads to significant underlying liver damage in an individual 
thereby increasing the susceptibility to potential hepatotoxic drugs. Furthermore, 
HCV/HIV co-infection has been demonstrated to result in accumulation of functional 
HIV-specific T-cells in the liver thereby resulting in accelerated progression of liver 
disease [36]. Even though HCV infection status is not measured at baseline in this 
cohort, the low rates of HIV/HCV co-infection in southern Africa [31] could explain 
the low incidence rates of severe hepatotoxicity in this cohort. 
 
A South African cohort in a mining environment had an incidence rate of severe 
hepatotoxicity of 77.0 events per 1000 p-yrs of follow-up time within a year of 
initiating HAART [26]. The individuals included in this cohort differed from our cohort 
in that more than half of the patients were on anti-tuberculous treatment at initiation 
of HAART compared to only a fifth in our study cohort. Three of the four drugs used 
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as first-line agents in tuberculosis treatment (Isoniazid, rifampicin and pyrazinamide) 
are known hepatotoxins. Furthermore, tuberculosis may result in immune 
reconstitution inflammatory syndrome (IRIS) if HAART is started at the same time 
with tuberculosis drugs. Usually, IRIS leads to transaminase elevation due to 
immune surveillance of mycobacterial antigens in the liver. The lower incidence rate 
of severe hepatotoxicity in our cohort compared to the South African mining cohort 
could therefore be attributed to a small proportion of individuals on anti-tuberculous 
drugs at initiation of HAART. Previous studies have also demonstrated increased 
incidence of hepatotoxicity in patients on both HAART and anti-tuberculous 
treatment [48-49].  
 
Our findings showed that the first two months of initiating HAART had the highest 
period incidence rate of severe hepatotoxicity. Thereafter, the incidence rate 
gradually decreases.  This is in keeping with the findings of previous studies [22, 50-
51]. The predominance of cases of severe hepatotoxicity early during treatment 
suggests that HAART-induced hepatotoxicity is less likely to be problematic with 
increasing treatment duration. 
 
Risk factors for severe hepatotoxicity 
Univariate analysis showed that only age and HAART regimen were significantly 
associated with the development of severe hepatotoxicity following initiation of 
HAART. The estimates for baseline ALT also suggested an increased risk of severe 
hepatotoxicity, though imprecise.  However, after adjusting for potential confounders 
in a multivariate model, HAART regimen was the only factor independently 
associated with the development of severe hepatotoxicity. 
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The increased risk of severe hepatotoxicity in individuals on a nevirapine-based 
regimen compared to those on an efavirenz-based regimen (2.07 times higher) 
follows similar trends observed in previous studies [14-15, 22]. It is for this reason 
that a “black-box” warning has been issued for nevirapine-based HAART [8].   
 
Correlation between recorded clinical diagnosis and laboratory diagnosis  
The correlation between recorded clinical diagnosis and laboratory diagnosis of 
severe hepatotoxicity during follow-up visits was only 18.2%. This proportion is very 
low considering the fact that hepatotoxicity can lead to treatment interruption, clinical 
hepatitis and even death.  
Several factors may account for the low correlation between recorded clinical 
diagnosis and laboratory diagnosis of severe hepatotoxicity. Firstly, the high number 
of patients may put a lot of pressure on doctors to an extent that they are less 
thorough during patient examination and review of results. Clinical outpatient settings 
may also not have information from inpatient diagnosis recorded thereby missing 
these patients. The definition for severe hepatotoxicty used by the clinicians could 
have been different from the study definitions thereby resulting in the low correlation. 
Clinicians were not the only people entering data into Therapy Edge-HIV TM. The use 
of lay data capturers to enter data into Therapy Edge-HIV TM in previous years may 
have also contributed to the low correlation since they are non-medical staff. 
Furthermore, doctors might not actively look for the diagnosis of hepatotoxicity 
because of limited knowledge about the possible consequences of the clinical 
condition. 
 
Strengths and Limitations 
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While the study reflects what happens in real clinical settings, the results should be 
interpreted with some caution considering a number of limitations. 
Loss to follow-up is a common limitation in observational cohort studies and may 
introduce bias to estimates if the individuals lost to follow-up had a different pattern 
of exposure variables and severe hepatotoxicity from those retained in the cohort. 
The results of this study should therefore be interpreted with some caution 
considering the attrition rate of 20.3%  
In reality, all HAART drugs have the potential of causing severe hepatotoxicity [8-9]  
but the attribution of severe hepatotoxicity to a single agent (nevirapine-based or 
efavirenz-based regimens) can be arbitrary and not reflect the real contribution of 
each drug to liver toxicity. However, the NNRTI class of antiretroviral drugs have 
been implicated in most cases of liver toxicity [8-9] and hence the categorisation. 
The above results should therefore be interpreted while aware of the fact that all 
HAART drugs have a potential of causing severe hepatotoxicity. 
 
It is important to recognise possible limitations of this study in terms of HAART 
regimen comparisons. Different frequencies in the measurement of liver function, 
which resulted in more frequent ALT monitoring in the nevirapine-based cohort, may 
have led to an increased detection of severe hepatotoxicity in that group compared 
to the efavirenz-based cohort. However, the observed association is consistent with 
findings from studies done elsewhere [14, 22, 28]. This finding suggests that careful 
management of patients on a nevirapine-based regimen, with a strict patient follow-
up should be done. 
Smoking status, alcohol intake status, baseline BMI, age at initiation, baseline CD4 
count, history of tuberculosis at initiation and gender did not appear to have any 
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significant effect on development of severe hepatotoxicity following initiation of 
HAART. However, variables which are not reliably measured in individuals, 
especially alcohol intake, could have resulted in residual confounding. 
  
Unlike in experimental studies where treatment arms are randomly assigned to 
individuals, in observational studies clinicians may assign an individual with a high 
risk of developing hepatotoxicity a regimen which is assumed to have better liver 
tolerability. Regardless of this shortfall, the study results reflect the experience of a 
large cohort in a real clinical setting compared to randomised controlled trials. 
 
HBV and HCV infection status of individuals are not routinely measured at the start 
of HAART at Themba Lethu clinic. While HIV/HBV co-infection is more common in 
some parts of sub-Saharan Africa than in resource-rich settings [20, 32], HIV/HCV 
co-infection has been reportedly less common [31].  These factors have been cited 
several times in previous studies as predictors of severe hepatotoxicity following 
HAART initiation [12-13, 26, 28, 33-35]. Absence of these variables might have led 
to exaggeration or lack of association between a possible predictor and severe 
hepatotoxicity as hepatitis infection status would not be adjusted for during analysis. 
These results should therefore be interpreted while cognisant of this fact.  
Inclusion of these and other possible predictors of hepatotoxicity in the analysis 
would help improve model fitness.  
Interpretation of the study results should also be made while aware of the fact that 
there may have been residual confounding. Variables such as smoking and alcohol 
use can cause limitations in the ability to control for confounding due to the imprecise 
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nature of their measurement and may result in residual confounding.  However, no 
studies in our setting have shown that this is likely to be a problem. 
Individuals excluded from the study on the basis of absent baseline ALT results 
could have biased our estimates if they had a different pattern of exposure variables 
and severe hepatotoxicity from those retained in the cohort. The differences in 
HAART regimen and baseline haemoglobin in patients excluded from the study on 
basis of missing baseline ALT results and the study sample warrants a cautious 
interpretation of the results. As Nevirapine is confirmed as a risk factor for 
hepatotoxicity, excluding these patients may have led to the underestimation of the 
estimate of severe hepatotoxicity 
Secondary data analysis of a prospective cohort study is highly dependent on good 
records and therefore if the database has missing data or some inaccuracies in 
patients’ information, misclassification of exposure variables can occur. This might 
therefore lead to bias in estimates. Therapy Edge-HIV TM uses an electronic data 
capturing system which minimises errors during data entry. All data used in this 
study was obtained from variables already captured on this electronic database.  
 
Generalizability 
This study presents data from a single urban government antiretroviral clinic. While 
the cohort is large, possible differences in characteristics of individuals in this cohort 
and other antiretroviral roll-out clinics in South Africa may limit the generalizability of 
our study findings beyond the study population. Themba Lethu clinic mainly caters 
for the urban populace that may have socio-demographic, clinical and treatment 
factors which may be different from their rural counterparts and those accessing care 
in the private sector.   
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CHAPTER FIVE 
 
 
CONCLUSION AND RECOMMENDATIONS  
The precision of the above estimates is, to some extent, compromised by a number 
of limitations. The poor retention of patients in this cohort increases the uncertainty 
of the calculated risks of severe hepatotoxicity. In order to improve follow-up of 
clients in the cohort, a strong system of obtaining data on patients who are 
transferred to other health facilities should be considered.  
 
The correlation of clinical and laboratory diagnosis of severe hepatotoxicty was low, 
considering the possible consequences of severe hepatotoxicity. It is therefore highly 
recommended that the factors that may impair the clinicians’ ability to correctly 
diagnose severe hepatotoxicity and data entry need to be addressed. These include 
the review of the doctor-patient ratio and conducting refresher courses aimed at 
equipping doctors with knowledge to help in the diagnosis. 
 
The high incidence rate of severe hepatotoxicity in the first two months of initiating 
HAART necessitates more frequent and careful monitoring of blood ALT levels early 
during therapy. This will identify the majority of the cases severe hepatotoxicity and 
allow appropriate interventions to be instituted.  
 
Poor model fitness in analysis suggests that there may be important predictors of 
severe hepatotoxicity which were not included in the model. One such factor may 
have been HBV infection status. It is therefore highly recommended that further 
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studies that measure important possible predictors of severe hepatotoxicty like HBV 
infection status be conducted. 
 
In order to minimise possible effects of detection bias, studies which will investigate 
factors for hepatotoxicity when ALT levels are measured at similar intervals for both 
the nevirapine-based and efavirenz-based groups need to be undertaken. 
  
Further studies which include participants from different South African settings are 
highly recommended in order to obtain results which can be generalised.  
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Appendix D 
Age and haemoglobin distribution 
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The histograms and Box and Whisker plots above suggest normal distribution of 
Age at initiation and baseline Haemoglobin and therefore it is appropriate to use 
means and standard deviations to describe these characteristics 
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Appendix E 
Baseline CD4 count and ALT distribution 
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The histograms (with superimposition of the normal curve) and the probability 
plots do not suggest normal distribution of baseline CD4 count and baseline ALT 
levels and therefore it is appropriate to use interquartile ranges to describe these 
characteristics    
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Appendix F 
Stphplot for baseline ALT, gender and HAART regimen 
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Stphplot: The plots of ALT, gender and HAART regimen against log of follow-up 
time shown above suggests that the proportional hazard assumption is not 
violated due to the parallel nature of the plots. However, the CD4 count plot 
suggests some minor violation of this assumption  
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Appendix G 
K-M plots plotted against predicted values 
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Stcoxkm: K-M plots plotted against Cox predicted values. The proportional hazard 
assumption is unlikely to have been violated as the observed values are very close to 
the predicted 
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Appendix H 
Global Spthtest  
 
The spthtest   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                      
      global test                        6.40        7         0.4935
                                                                      
      ALT_baseline       0.09735         0.79        1         0.3727
      _IHAARTreg~1      -0.15444         1.94        1         0.1634
      age_at_ini~n      -0.03336         0.08        1         0.7789
      _ICD4_Cat_3        0.16645         2.28        1         0.1313
      _ICD4_Cat_2        0.18926         2.88        1         0.0899
      _ICD4_Cat_1        0.10398         0.89        1         0.3451
      _Igender_2         0.05459         0.25        1         0.6205
                                                                      
                          rho            chi2       df       Prob>chi2
                                                                      
      Time:  Time
      Test of proportional-hazards assumption
Spthtest: globally, the assumption of 
proportional hazards was met as p>0.005. 
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Appendix:  I 
Martingale residuals plotted against survival time 
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Model adequacy was tested by 
calculating and plotting Martingale 
residuals against survival time. The plot 
suggests that the Cox model fits the 
data poorly 
 
